It was a great pleasure to meet up with Marwan Sabbagh (Cleveland Clinic Lerner College of Medicine, Las Vegas, NV, USA), to discuss the recent approval of aducanumab for Alzheimer’s Disease. Aducanumab was granted accelerated approval on June 7 2021, by the U.S. Food and Drug Administration (FDA).
Questions:
- Could you give us a brief overview of the clinical trial program that has led to the approval of aducanumab for Alzheimer’s disease? (0:09)
- Could you tell us more about the ongoing EMBARK study? (1:38)
- Why has aducanumab succeeded when so many other drugs have failed late stage clinical trials? (2:07)
- What are the challenges and opportunities presented by this approval? (4:01)
- What questions remain unanswered and what future studies are planned? (5:30)
Disclosures: Marwan Sabbagh receives research support from the NIH and the Keep Memory Alive Foundation; consulting agreements with Alzheon, Biogen, Cortexyme, Danone, Neurotrope, Regenron, Stage 2 Innovations, Acadia, and Roche-Genentech; stock options in Brain Health Inc., NeuroReserve, NeuroTau, Optimal Cognitive Health Co., uMethod Health,Versanum Inc. and Athira.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch
